skip to Main Content

Homogeneous antibody and CAR-T Cells with Improved Effector Functions Targeting SSEA-4 Glycan on Pancreatic Cancer

Newsfeed image, light gray text on dark gray background

Pancreatic cancer treatments remain challenging due to late diagnosis and intrinsic resistance to conventional treatments. In this study, we demonstrate the use of the homogeneous SSEA-4 antibody and CAR-T cells for effective treatment in pancreatic cancer and suggest that targeting SSEA-4 has the potential to treat pancreatic cancer.

Pancreatic cancer is usually asymptomatic in the early stages; the 5-y survival rate is around 9%; and there is a lack of effective treatment. Here we show that SSEA-4 is more expressed in all pancreatic cancer cell lines examined but not detectable in normal pancreatic cells; and high expression of SSEA-4 or the key enzymes B3GALT5 + ST3GAL2 associated with SSEA-4 biosynthesis significantly lowers the overall survival rate. Read more . . . 

Back To Top